Committee Chair Succession & Director Declaration
Source: RNS
27 February 2023
Centrica plc
('Centrica' or 'the Company')
COMMITTEE CHAIR SUCCESSION AND DIRECTOR DECLARATION
In accordance with Listing Rule 9.6.11, Centrica today announces that Nathan Bostock will succeed Kevin O'Byrne as Chair of the Company's Audit and Risk Committee with effect from 1 March 2023.
In addition, further to the announcement today by International Flavors & Fragrances Inc. ('IFF') and in accordance with Listing Rule 9.6.14R (2), Centrica further announces that Kevin O'Byrne has been appointed as a Non-Executive Director of IFF, listed on the NYSE, with effect from 10 March 2023.
Kevin O'Byrne has served as Chair of the Company's Audit and Risk Committee for approaching 4 years and will remain the Company's Senior Independent Director.
Nathan Bostock was appointed a Non-Executive Director of the Company on 9 May 2022 and has been a member of the Company's Audit and Risk Committee since that date.
ENDS
Enquiries:
Investors and Analysts
T: 01753 494900
E: ir@centrica.com
Media
T: 01784 843000
E: media@centrica.com
Centrica plc is listed on the London Stock Exchange (CNA)
Registered Office: Millstream, Maidenhead Road, Windsor, Berkshire SL4 5GD
Registered in England & Wales number: 3033654
Legal Entity Identifier number: E26EDV109X6EEPBKVH76
ISIN number: GB00B033F229
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
